Barclays PLC Lowers Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Barclays PLC lessened its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 24.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 323,496 shares of the company's stock after selling 104,099 shares during the period. Barclays PLC's holdings in Teva Pharmaceutical Industries were worth $7,129,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of TEVA. Diversify Advisory Services LLC lifted its holdings in Teva Pharmaceutical Industries by 2.5% during the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock worth $426,000 after buying an additional 496 shares during the period. Thrivent Financial for Lutherans grew its stake in Teva Pharmaceutical Industries by 0.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock valued at $4,964,000 after purchasing an additional 699 shares during the last quarter. Townsquare Capital LLC grew its position in shares of Teva Pharmaceutical Industries by 2.1% in the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock worth $885,000 after buying an additional 812 shares during the last quarter. Metis Global Partners LLC increased its position in shares of Teva Pharmaceutical Industries by 6.7% during the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock worth $302,000 after purchasing an additional 860 shares in the last quarter. Finally, DGS Capital Management LLC raised its stake in Teva Pharmaceutical Industries by 6.8% in the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock valued at $246,000 after buying an additional 872 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA traded down $0.07 during mid-day trading on Wednesday, hitting $15.51. The stock had a trading volume of 8,892,611 shares, compared to its average volume of 9,953,171. The firm's 50 day moving average is $15.16 and its 200 day moving average is $17.53. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The stock has a market capitalization of $17.59 billion, a price-to-earnings ratio of -10.70, a PEG ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a twelve month low of $12.47 and a twelve month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Barclays decreased their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. UBS Group reduced their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, April 23rd. Piper Sandler raised their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. Finally, Bank of America dropped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.